Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

Table 3.1 is amended as follows: the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
007-004-00-1	nitric acid … %	231-714-2	7697-37-2	Ox. Liq. 2 Skin Corr. 1A	H272 H314	GHS03 GHS05 Dgr	H272 H314	EUH071	Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 %	B
015-003-00-2	calcium phosphide; tricalcium diphosphide	215-142-0	1305-99-3	Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1	H260 H300 H311 H330 H318 H400	GHS02 GHS06 GHS05 GHS09 Dgr	H260 H300 H311 H330 H318 H400	EUH029 EUH032	M = 100
031-001-00-4	gallium arsenide	215-114-8	1303-00-0	Repr. 1B Carc. 1B STOT RE 1	H360F H350 H372 (respiratory and haematopoietic systems)	GHS08 Dgr	H360F H350 H372 (respiratory and haematopoietic systems)
050-008-00-3	tributyltin compounds, with the exception of those specified elsewhere in this annex	—	—	Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H360FD H301 H312 H372** H315 H319 H400 H410	GHS08 GHS06 GHS09 Dgr	H360FD H301 H312 H372** H315 H319 H410		* STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10	A 1
603-102-00-9	1,2-epoxybutane	203-438-2	106-88-7	Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2	H225 H351 H302 H312 H332 H335 H315 H319	GHS02 GHS08 GHS07 Dgr	H225 H351 H302 H312 H332 H335 H315 H319
603-197-00-7	tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol	403-640-2	107534-96-3	Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H361d*** H302 H400 H410	GHS08 GHS07 GHS09 Wng	H361d*** H302 H410		M = 1 M = 10
606-054-00-7	isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone	—	141112-29-0	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d*** H400 H410	GHS08 GHS09 Wng	H361d*** H410		M = 10 M = 100
607-197-00-8	nonanoic acid	203-931-2	112-05-0	Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3	H315 H319 H412	GHS07 Wng	H315 H319 H412
613-042-00-5	imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole	252-615-0	35554-44-0	Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1	H351 H301 H332 H318 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H351 H301 H332 H318 H410		M = 10
613-057-00-7	dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine	216-474-9	1593-77-7	Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H361d H373 (liver) H314 H317 H400 H410	GHS08 GHS05 GHS07 GHS09 Dgr	H361d H373 (liver) H314 H317 H410	EUH071	M = 1 M = 1
613-133-00-X	etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole	219-991-8	2593-15-9	Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H302 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H302 H317 H410		M = 1 M = 1
613-149-00-7	pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one	405-700-3	96489-71-3	Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H331 H301 H400 H410	GHS06 GHS09 Dgr	H331 H301 H410		M = 1 000 M = 1 000

the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)
019-003-00-3	potassium (E,E)-hexa-2,4-dienoate	246-376-1	24634-61-5	Eye Irrit. 2	H319	GSH07 Wng	H319
604-092-00-9	phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2]	310-154-3 [1]	121158-58-5 [1] 74499-35-7 [2]	Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1	H314 H400 H410	GHS05 GHS09 Dgr	H314 H410		M = 10 M = 10
606-148-00-8	carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]	202-759-5 [1] 218-827-2 [2] 229-352-5 [3]	99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3]	Skin Sens. 1	H317	GHS07 Wng	H317
606-149-00-3	tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione	—	335104-84-2	Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H361d H373 (eyes, kidneys, liver) H317 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H373 (eyes, kidneys, liver) H317 H410		M = 100 M = 10
607-707-00-9	fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate	—	71283-80-2	STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H373 (kidneys) H317 H400 H410	GHS08 GHS07 GHS09 Wng	H373 (kidneys) H317 H410		M = 1 M = 1
607-708-00-4	octanoic acid	204-677-5	124-07-2	Skin Corr. 1C Aquatic Chronic 3	H314 H412	GHS05 Dgr	H314 H412
607-709-00-X	decanoic acid	206-376-4	334-48-5	Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3	H315 H319 H412	GHS07 Wng	H315 H319 H412
607-710-00-5	1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear	271-093-5	68515-50-4	Repr. 1B	H360FD	GHS08 Dgr	H360FD
607-711-00-0	spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate	—	203313-25-1	Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H361fd H335 H319 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H361fd H335 H319 H317 H410		M = 1 M = 1
607-712-00-6	dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate	250-778-2	31717-87-0	Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1	H361d H373 (liver) H314 H317 H410	GHS08 GHS05 GHS07 GHS09 Dgr	H361d H373 (liver) H314 H317 H410	EUH071	M = 1
607-713-00-1	fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate	—	134098-61-6	Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H301 H330 H317 H400 H410	GHS06 GHS09 Dgr	H301 H330 H317 H410		M = 100 M = 1 000
607-714-00-7	triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate	—	126535-15-7	Carc. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 100 M = 10
607-715-00-2	bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate	442-820-5	149877-41-8	STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H373 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H373 H317 H410		M = 1 M = 1
613-319-00-0	imidazole	206-019-2	288-32-4	Repr. 1B Acute Tox. 4 Skin Corr. 1C	H360D H302 H314	GHS08 GHS07 GHS05 Dgr	H360D H302 H314
613-320-00-6	lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione	218-499-0	2164-08-1	Carc. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 10 M = 10
616-213-00-2	mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide	—	374726-62-2	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1
616-214-00-8	metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide	—	139528-85-1	Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H373 (eyes, kidneys) H400 H410	GHS08 GHS09 Wng	H351 H373 (eyes, kidneys) H410		M = 1 000 M = 100
616-215-00-3	dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide	—	163515-14-8	Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H317 H400 H410	GHS07 GHS09 Wng	H302 H317 H410		M = 10 M = 10
616-216-00-9	flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide	—	158062-67-0	Acute Tox. 4	H302	GHS07 Wng	H302
616-217-00-4	sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide	—	946578-00-3	Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H302 H400 H410	GHS07 GHS09 Wng	H302 H410		M = 1 M = 1

Table 3.2 is amended as follows: the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No	International Chemical Identification	EC No	CAS No	Classification	Labelling	Concentration Limits	Notes
007-004-00-1	nitric acid … %	231-714-2	7697-37-2	O; R8 C; R35	O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63	O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 %	B
015-003-00-2	calcium phosphide; tricalcium diphosphide	215-142-0	1305-99-3	F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50	F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61	N; R50: C ≥ 0,25 %
031-001-00-4	gallium arsenide	215-114-8	1303-00-0	Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23	T R: 45-48/23-60 S: 45-53		E
050-008-00-3	tributyltin compounds, with the exception of those specified elsewhere in this annex	—	—	Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53	T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61	T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %	A 1
603-102-00-9	1,2-epoxybutane	203-438-2	106-88-7	F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38	F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46
603-197-00-7	tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol	403-640-2	107534-96-3	Repr. Cat. 3; R63 Xn; R22 N; R50-53	Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 %
606-054-00-7	isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone	—	141112-29-0	Repr. Cat. 3; R63 N; R50-53	Xn; N R: 50/53-63 S: (2-)36/37-60-61	N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %
607-197-00-8	nonanoic acid	203-931-2	112-05-0	Xi; R36/38 N; R51-53	Xi; N R: 36/38-51/53 S: (2-)46-61
613-042-00-5	imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole	252-615-0	35554-44-0	Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53	Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61
613-057-00-7	dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine	216-474-9	1593-77-7	Repr. Cat. 3; R63 C; R34 R43 N; R50-53	C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61	C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
613-133-00-X	etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole	219-991-8	2593-15-9	Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53	Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
613-149-00-7	pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one	405-700-3	96489-71-3	T; R23/25 N; R50-53	T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61	N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 %

the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

Index No	International Chemical Identification	EC No	CAS No	Classification	Labelling	Concentration Limits	Notes
019-003-00-3	potassium (E,E)-hexa-2,4-dienoate	246-376-1	24634-61-5	Xi; R36	Xi R: 36 S: (2-)25-46
604-092-00-9	phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2]	310-154-3 [1]-[2]	121158-58-5 [1] 74499-35-7 [2]	C; R34 N; R50-53	C; N R: 34-50/53 S: (1/2-)26-36/37/39-45-61	N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %
606-148-00-8	carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]	202-759-5 [1] 218-827-2 [2] 229-352-5 [3]	99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3]	R43	Xi R: 43 S: (2-)24-37
606-149-00-3	tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione		335104-84-2	Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53	Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61	N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 %
607-707-00-9	fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate	—	71283-80-2	Xn; R48/22 R43 N; R50-53	Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
607-708-00-4	octanoic acid	204-677-5	124-07-2	C; R34 N; R51-53	C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61
607-709-00-X	decanoic acid	206-376-4	334-48-5	Xi; R36/38 N; R51-53	Xi; N R: 36/38-51/53 S: (2-)25-46-61
607-710-00-5	1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear	271-093-5	68515-50-4	Repr. Cat. 2; R60-61	T R: 60-61 S: 53-45
607-711-00-0	spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate	—	203313-25-1	Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53	Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61	Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
607-712-00-6	dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate	250-778-2	31717-87-0	Repr. Cat. 3; R63 C; R34 R43 N; R51-53	C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61	C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 %
607-713-00-1	fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate	—	134098-61-6	T+; R26 Xn; R22 R43 N; R50-53	T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63	N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 %
607-714-00-7	triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate	—	126535-15-7	Carc. Cat. 3; R40 N; R50-53	Xn; N R: 40-50/53 S: (2-)36/37-60-61	N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 %
607-715-00-2	bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate	442-820-5	149877-41-8	R43 N; R50-53	Xi; N R: 43-50/53 S: (2-)24-37-60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %
613-319-00-0	imidazole	206-019-2	288-32-4	Repr. Cat 2; R61 Xn; R22 C; R34	T; C R: 22-34-61 S: 53-45
613-320-00-6	lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione	218-499-0	2164-08-1	Carc. Cat. 3; R40 N; R50-53	Xn; N R: 40-50/53 S: (2-)36/37-60-61	N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %
616-213-00-2	mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide	—	374726-62-2	N; R50-53	N R: 50/53 S: 60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 %
616-214-00-8	metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide	—	139528-85-1	Carc. Cat. 3; R40 Xn; R48/22 N; R50-53	Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61	N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 %
616-215-00-3	dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide	—	163515-14-8	Xn; R22 R43 N; R50-53	Xn; N R: 22-43-50/53 S: (2-)24-37-60-61	N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 %
616-216-00-9	flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide	—	158062-67-0	Xn; R22	Xn R: 22 S: (2-)46
616-217-00-4	sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide	—	946578-00-3	Xn; R22 N; R50-53	Xn; N R: 22-50/53 S: (2-)60-61	N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %